Orforglipron
A small-molecule oral GLP-1 receptor agonist studied as a needle-free alternative to injectable incretin therapy.
Overview
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist taken orally. It represents the next generation of GLP-1 therapy — providing weight-loss and glycemic effects without the need for refrigerated, injectable formulations.
Benefits
- Effective oral GLP-1 administration (no injection)
- Reduces appetite and supports weight loss
- Improves glycemic control
- Potential for greater accessibility vs. injectables
Mechanism of Action
Orforglipron is a non-peptide agonist that binds and activates the GLP-1 receptor. The activation cascade enhances glucose-dependent insulin release, suppresses glucagon, and signals satiety in appetite-regulating brain regions.
Dosage (informational only)
- Typical range
- 3–45 mg per day (trial range)
- Frequency
- Once daily, oral
Currently investigational. Designed for use without water and food restrictions, unlike older oral GLP-1s.
Side Effects
- Nausea and vomiting
- Diarrhea or constipation
- Decreased appetite
- Possible elevated heart rate
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.